Brief: Jenscare Scientific Says Lux-Valve Plus Receives FDA IDE Approval For Pivotal Trial
06/02/2026 13:56
Feb 6 (Reuters) - Jenscare Scientific Co Ltd 9877.HK: LUX-VALVE PLUS RECEIVES FDA IDE APPROVAL FOR PIVOTAL TRIAL Further company coverage: 9877.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jenscare Scientific Co
See all newsBrief: Jenscare Scientific Says Ken-Valve Transcatheter Aortic Valve Replacement System Receives HK Approval
Brief: Jenscare Scientific Posts FY Revenue Of RMB90.6 Million
Brief: Jenscare Scientific Appoints Li Yuanyuan As CFO
Brief: Jenscare Scientific Receives NZ Approval For Ken-Valve And Lux-Valve Plus
Brief: Jenscare Scientific Says Lux-Valve Plus Receives FDA IDE Approval For Pivotal Trial